Physician profile
Vineeth Mohan
NPI 1023059730
$50,759.26
in general payments reported to CMS, 2019-2025
22 companies · $8,613 in 2025
The $8,613 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $2,326 · 2021: $12K · 2022: $13K · 2023: $8,886 · 2024: $6,177 · 2025: $8,613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $13K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,177 · Food and Beverage: $1,561 · Travel and Lodging: $686 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $13,217.22 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,177.00 |
| Food and Beverage | $1,560.58 |
| Travel and Lodging | $685.60 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $41,071.10 | 2019-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Ascendis Pharma Endocrinology INC | $8,189.97 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $226.26 | 2024-2025 | |
| Corcept Therapeutics | $160.90 | 2024-2025 | Korlym |
| Sequel Med Tech, LLC | $152.31 | 2025 | Twiist |
| Argenx US, INC. | $125.00 | 2024 | |
| Amgen INC. | $124.28 | 2019-2025 | Tepezza |
| Novo Nordisk INC | $118.40 | 2019-2024 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $109.24 | 2020 | |
| Insulet Corporation | $88.28 | 2019 | |
| Xeris Pharmaceuticals, INC. | $57.07 | 2024-2025 | Gvoke Hypopen, Recorlev |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.07 | 2025 | Jardiance |
| Alkermes, INC. | $47.48 | 2025 | Aristada, Lybalvi |
| Ucb, INC. | $47.05 | 2021 | |
| Lilly USA, LLC | $39.46 | 2022-2025 | Zepbound, Mounjaro |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lifescan, INC. | $33.46 | 2019 | |
| Neurocrine Biosciences, INC. | $28.65 | 2024 | |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Madrigal Pharmaceuticals | $20.42 | 2025 | Rezdiffra |
| Millicent US INC | $13.89 | 2023 | Femring, Intrarosa |
| Medtronic Minimed, INC. | $13.40 | 2019 | |
| Cequr Corporation | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vineeth Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.